JP2013518832A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013518832A5 JP2013518832A5 JP2012551506A JP2012551506A JP2013518832A5 JP 2013518832 A5 JP2013518832 A5 JP 2013518832A5 JP 2012551506 A JP2012551506 A JP 2012551506A JP 2012551506 A JP2012551506 A JP 2012551506A JP 2013518832 A5 JP2013518832 A5 JP 2013518832A5
- Authority
- JP
- Japan
- Prior art keywords
- cyy
- nyy
- atoms
- het
- hal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004432 carbon atom Chemical group C* 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 9
- 125000004430 oxygen atom Chemical group O* 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000004434 sulfur atom Chemical group 0.000 claims 5
- 125000002619 bicyclic group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 239000003607 modifier Substances 0.000 claims 3
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000000169 tricyclic heterocycle group Chemical group 0.000 claims 2
- 102100032187 Androgen receptor Human genes 0.000 claims 1
- 102100038595 Estrogen receptor Human genes 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 108010080146 androgen receptors Proteins 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 108010038795 estrogen receptors Proteins 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 239000004030 hiv protease inhibitor Substances 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000027483 retinoid hormone receptors Human genes 0.000 claims 1
- 108091008679 retinoid hormone receptors Proteins 0.000 claims 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 1
- 239000003558 transferase inhibitor Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10001251 | 2010-02-05 | ||
| EP10001251.7 | 2010-02-05 | ||
| PCT/EP2010/007743 WO2011095196A1 (en) | 2010-02-05 | 2010-12-17 | Hetaryl-[1,8]naphthyridine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013518832A JP2013518832A (ja) | 2013-05-23 |
| JP2013518832A5 true JP2013518832A5 (OSRAM) | 2014-09-04 |
| JP5675850B2 JP5675850B2 (ja) | 2015-02-25 |
Family
ID=43531801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012551506A Expired - Fee Related JP5675850B2 (ja) | 2010-02-05 | 2010-12-17 | ヘタリール−［１，８］ナフチリジン誘導体 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8614226B2 (OSRAM) |
| EP (1) | EP2531500B1 (OSRAM) |
| JP (1) | JP5675850B2 (OSRAM) |
| KR (1) | KR20120124469A (OSRAM) |
| CN (1) | CN102741249B (OSRAM) |
| AU (1) | AU2010344973B2 (OSRAM) |
| BR (1) | BR112012018954A2 (OSRAM) |
| CA (1) | CA2789021C (OSRAM) |
| EA (1) | EA201201081A1 (OSRAM) |
| ES (1) | ES2667049T3 (OSRAM) |
| MX (1) | MX2012008550A (OSRAM) |
| SG (1) | SG182803A1 (OSRAM) |
| WO (1) | WO2011095196A1 (OSRAM) |
| ZA (1) | ZA201206630B (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA022064B1 (ru) * | 2010-02-22 | 2015-10-30 | Мерк Патент Гмбх | Гетариламинонафтиридины в качестве ингибиторов атф-связывающих белков |
| PE20130376A1 (es) * | 2010-06-28 | 2013-03-30 | Merck Patent Gmbh | [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer |
| EP2591115B1 (en) * | 2010-07-07 | 2018-12-05 | Dow AgroSciences LLC | Production of functionalized linear dna cassette and quantum dot/nanoparticle mediated delivery in plants |
| KR20130118612A (ko) * | 2012-04-20 | 2013-10-30 | (주)네오믹스 | 신규한 아미노피리딘 유도체 및 이의 용도 |
| WO2014055595A1 (en) | 2012-10-05 | 2014-04-10 | Merck Sharp & Dohme Corp. | Indoline compounds as aldosterone synthase inhibitiors related applications |
| MX2015004151A (es) * | 2012-10-05 | 2015-07-06 | Rigel Pharmaceuticals Inc | Inhibidores del factor de diferenciacion de crecimiento-8 (gdf-8). |
| PE20151979A1 (es) | 2013-01-23 | 2016-01-15 | Astrazeneca Ab | Compuestos quimicos |
| CN103113369A (zh) * | 2013-03-21 | 2013-05-22 | 云南大学 | 一种具有抗肿瘤活性的苯并[b][1,8]-萘啶-2-(1H)-亚胺衍生物及合成方法 |
| TWI529171B (zh) * | 2013-07-29 | 2016-04-11 | 赫孚孟拉羅股份公司 | １，７－萘啶衍生物 |
| WO2015081257A2 (en) | 2013-11-27 | 2015-06-04 | Signalchem Lifesciences Corporation | Aminopyridine derivatives as tam family kinase inhibitors |
| TN2016000270A1 (en) | 2014-01-14 | 2017-10-06 | Millennium Pharm Inc | Heteroaryls and uses thereof. |
| JP2017502092A (ja) | 2014-01-14 | 2017-01-19 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ヘテロアリール及びその使用 |
| EP3129367B1 (en) * | 2014-04-08 | 2019-09-04 | Rigel Pharmaceuticals, Inc. | 2,3-disubstituted pyridine compounds as tgf-beta inhibitors |
| PT3762368T (pt) | 2018-03-08 | 2022-05-06 | Incyte Corp | Compostos de aminopirazina diol como inibidores de pi3k-y |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| WO2021142086A1 (en) | 2020-01-08 | 2021-07-15 | Synthis Therapeutics, Inc. | Alk5 inhibitor conjugates and uses thereof |
| WO2024258967A1 (en) | 2023-06-13 | 2024-12-19 | Synthis Therapeutics, Inc. | Anti-cd5 antibodies and their uses |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR207555A1 (es) | 1972-12-04 | 1976-10-15 | Procedimiento para preparar aril-6-piperazinocarboniloxi-5 oxo-7 tetrahidro-2,3,6,7 ditiino(1,4)(2,3-c)pirroles | |
| IT1245712B (it) | 1991-04-09 | 1994-10-14 | Boehringer Mannheim Italia | Ammine eterocicliche utili terapia dell'asma e dell'infiammazione delle vie aeree |
| US5994367A (en) * | 1997-03-07 | 1999-11-30 | The University Of North Carolina At Chapel Hill | Method for treating tumors using 2-aryl-naphthyridin-4-ones |
| BR9813279B1 (pt) * | 1997-10-27 | 2010-11-16 | derivado de homopiperazina, composição farmacêutica, e, uso do derivado de homopiperazina. | |
| AU4972900A (en) | 1999-04-08 | 2000-11-14 | Arch Development Corporation | Use of anti-vegf antibody to enhance radiation in cancer therapy |
| GB0117060D0 (en) * | 2001-07-12 | 2001-09-05 | Merck Sharp & Dohme | Therapeutic agents |
| US20040038856A1 (en) * | 2002-05-17 | 2004-02-26 | Sarvajit Chakravarty | Treatment of fibroproliferative disorders using TGF-beta inhibitors |
| WO2004081009A1 (en) * | 2003-03-12 | 2004-09-23 | Millennium Pharmaceuticals, Inc. | Quinazoline derivatives as tgf-beta inhibitors |
| WO2005080377A1 (ja) | 2004-02-20 | 2005-09-01 | Kirin Beer Kabushiki Kaisha | TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
| EP2607362B1 (en) | 2005-02-17 | 2014-12-31 | Astellas Pharma Inc. | Piperidine and piperazine carboxylates as FAAH inhibitors |
| US7825137B2 (en) | 2005-12-05 | 2010-11-02 | Pfizer Inc. | Method of treating abnormal cell growth |
| JP4751856B2 (ja) | 2007-07-03 | 2011-08-17 | 本田技研工業株式会社 | 車体側部構造 |
| DE102007049451A1 (de) | 2007-10-16 | 2009-04-23 | Merck Patent Gmbh | 5-Cyano-thienopyridine |
| AR070127A1 (es) | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
| JP2011511005A (ja) | 2008-02-04 | 2011-04-07 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | ２−アミノピリジン系キナーゼ阻害薬 |
| DE102008017853A1 (de) | 2008-04-09 | 2009-10-15 | Merck Patent Gmbh | Thienopyrimidine |
| CN102015691B (zh) | 2008-04-29 | 2014-01-08 | 诺华股份有限公司 | 作为活化素样受体激酶(alk4或alk5)抑制剂的咪唑并吡啶衍生物 |
| MX2011013667A (es) * | 2009-06-25 | 2012-03-06 | Amgen Inc | Compuestos heterociclicos y sus usos. |
| EA022064B1 (ru) * | 2010-02-22 | 2015-10-30 | Мерк Патент Гмбх | Гетариламинонафтиридины в качестве ингибиторов атф-связывающих белков |
| PE20130376A1 (es) * | 2010-06-28 | 2013-03-30 | Merck Patent Gmbh | [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer |
-
2010
- 2010-12-17 WO PCT/EP2010/007743 patent/WO2011095196A1/en not_active Ceased
- 2010-12-17 EA EA201201081A patent/EA201201081A1/ru unknown
- 2010-12-17 ES ES10794897.8T patent/ES2667049T3/es active Active
- 2010-12-17 CA CA2789021A patent/CA2789021C/en not_active Expired - Fee Related
- 2010-12-17 US US13/574,282 patent/US8614226B2/en active Active
- 2010-12-17 MX MX2012008550A patent/MX2012008550A/es not_active Application Discontinuation
- 2010-12-17 JP JP2012551506A patent/JP5675850B2/ja not_active Expired - Fee Related
- 2010-12-17 CN CN201080063064.6A patent/CN102741249B/zh not_active Expired - Fee Related
- 2010-12-17 SG SG2012056495A patent/SG182803A1/en unknown
- 2010-12-17 AU AU2010344973A patent/AU2010344973B2/en not_active Ceased
- 2010-12-17 KR KR1020127022601A patent/KR20120124469A/ko not_active Withdrawn
- 2010-12-17 EP EP10794897.8A patent/EP2531500B1/en not_active Not-in-force
- 2010-12-17 BR BR112012018954A patent/BR112012018954A2/pt not_active IP Right Cessation
-
2012
- 2012-09-04 ZA ZA2012/06630A patent/ZA201206630B/en unknown
-
2013
- 2013-10-04 US US14/046,703 patent/US8912216B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013518832A5 (OSRAM) | ||
| JP2013507423A5 (OSRAM) | ||
| JP2010077141A5 (OSRAM) | ||
| JP2010265321A5 (OSRAM) | ||
| JP2014518884A5 (OSRAM) | ||
| JP2011516511A5 (OSRAM) | ||
| AR094262A1 (es) | Compuestos antivirales para el tratamiento de la hepatitis c | |
| JP2010527913A5 (OSRAM) | ||
| JP2013527242A5 (OSRAM) | ||
| TN2012000246A1 (en) | Pharmaceutical compositions comprising sigma receptor ligands | |
| JP2013514980A5 (OSRAM) | ||
| JP2011527299A5 (OSRAM) | ||
| JP2009530398A5 (OSRAM) | ||
| JP2015512946A5 (OSRAM) | ||
| JP2013510856A5 (OSRAM) | ||
| JP2011527345A5 (OSRAM) | ||
| JP2010090149A5 (OSRAM) | ||
| JP2017503760A5 (OSRAM) | ||
| JP2013500342A5 (OSRAM) | ||
| JP2014505017A5 (OSRAM) | ||
| JP2015509075A5 (OSRAM) | ||
| AR073117A1 (es) | Derivado de aminometil-fenil-piperidin-1-il-indolil-metanona, inhibidores de la triptasa de mastocitos, composiciones farmaceuticas que lo contienen, metodo de preparacion, compuestos intermediarios y uso del compuesto en el tratamiento de procesos inflamatorios. | |
| JP2013542980A5 (OSRAM) | ||
| JP2013513607A5 (OSRAM) | ||
| JP2010514734A5 (OSRAM) |